# Immatics (immatics)

Generated: `2026-02-03T11:03:52Z`

## KPIs

- Assets: **8**
- Assets with linked trials: **2**
- Trials: **5**

### Assets by stage
- Phase 1: **6**
- Preclinical: **2**

### Trials by status
- RECRUITING: **5**

## Top assets

| Asset | Highest stage | Linked trials | Example indications |
|---|---:|---:|---|
| anzu-cel | Phase 1 | 2 | 2L melanoma; 2L melanoma; 2L melanoma |
| mRNA-4203 | Phase 1 | 1 | Solid cancers (combo with anzu-cel / IMA203); Solid cancers (combo with anzu-cel / IMA203); Solid cancers (combo with anzu-cel / IMA203) |
| IMA402 + ICI | Phase 1 | 0 | Melanoma, gynecologic cancers, other solid cancers (combo); Melanoma, gynecologic cancers, other solid cancers (combo); Melanoma, gynecologic cancers, other solid cancers (combo) |
| IMA402 | Phase 1 | 0 | Melanoma, gynecologic cancers, other solid cancers; Melanoma, gynecologic cancers, other solid cancers; Melanoma, gynecologic cancers, other solid cancers |
| IMA401 | Phase 1 | 0 | HNSCC, sqNSCLC, other solid cancers; HNSCC, sqNSCLC, other solid cancers; HNSCC, sqNSCLC, other solid cancers |
| IMA203CD8 | Phase 1 | 0 | Gynecologic cancers; other solid cancers; Gynecologic cancers; other solid cancers; Gynecologic cancers; other solid cancers |
| Undisclosed cell therapy | Preclinical | 0 | Undisclosed; Undisclosed; Undisclosed |
| Undisclosed bispecific | Preclinical | 0 | Undisclosed; Undisclosed; Undisclosed |

## Recent changes

- `` **trials_ingested** — {"trials_seen": 5, "inserted": 5, "updated": 0, "status_changed": 0, "bad_aliases": 0}
- `` **trials_ingested** — {"trials_seen": 5, "inserted": 0, "updated": 5, "status_changed": 0, "bad_aliases": 0}
- `` **trials_ingested** — {"trials_seen": 5, "inserted": 0, "updated": 5, "status_changed": 0, "bad_aliases": 0}
- `` **trial_assets_linked** — {"nct_id": "NCT06946225", "linked_assets": 2}
- `` **trial_assets_linked** — {"nct_id": "NCT06743126", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT06946225", "linked_assets": 2}
- `` **trial_assets_linked** — {"nct_id": "NCT06743126", "linked_assets": 1}
- `` **trial_assets_linked** — {"nct_id": "NCT06946225", "linked_assets": 2}
- `` **trial_assets_linked** — {"nct_id": "NCT06743126", "linked_assets": 1}
- `` **trial_added** — {"nct_id": "NCT06946225", "title": "A First-in-human, Open-label Trial to Evaluate the Combination of ACTengine® IMA203 With mRNA-4203 in Previously Treated, Unresectable or Metast…
- `` **trial_added** — {"nct_id": "NCT03686124", "title": "Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in C…
- `` **trial_added** — {"nct_id": "NCT06743126", "title": "A Prospective, Multicenter, Open-label, Randomized, Actively Controlled, Parallel-group Phase 3 Clinical Trial to Evaluate Efficacy, Safety, and…
- `` **trial_added** — {"nct_id": "NCT05958121", "title": "A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific TCER® Targeting …
- `` **trial_added** — {"nct_id": "NCT05359445", "title": "A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of IMA401, a Bispecific T Cell …
- `` **pipeline_ingested** — {"pipeline_page": "https://immatics.com/our-pipeline/", "pipeline_image": "https://immatics.com/wp-content/uploads/2025/12/20251112_IMTX_pipeline_v3-scaled.png", "assets_seen": 8}
- `` **pipeline_ingested** — {"pipeline_page": "https://immatics.com/our-pipeline/", "pipeline_image": "https://immatics.com/wp-content/uploads/2025/12/20251112_IMTX_pipeline_v3-scaled.png", "assets_seen": 8}
- `` **pipeline_ingested** — {"pipeline_page": "https://immatics.com/our-pipeline/", "pipeline_image": "https://immatics.com/wp-content/uploads/2025/12/20251112_IMTX_pipeline_v3-scaled.png", "assets_seen": 8}
- `` **asset_indication_added** — {"asset": "anzu-cel", "indication": "Uveal melanoma", "stage": "Phase 1", "therapeutic_area": "Oncology"}
- `` **asset_indication_added** — {"asset": "anzu-cel", "indication": "Solid cancers (in combination with mRNA-4203)", "stage": "Phase 1", "therapeutic_area": "Oncology"}
- `` **asset_indication_added** — {"asset": "anzu-cel", "indication": "2L melanoma", "stage": "Phase 1", "therapeutic_area": "Oncology"}
- `` **asset_indication_added** — {"asset": "mRNA-4203", "indication": "Solid cancers (combo with anzu-cel / IMA203)", "stage": "Phase 1", "therapeutic_area": "Oncology"}
- `` **asset_indication_added** — {"asset": "IMA203CD8", "indication": "Gynecologic cancers; other solid cancers", "stage": "Phase 1", "therapeutic_area": "Oncology"}
- `` **asset_indication_added** — {"asset": "IMA402", "indication": "Melanoma, gynecologic cancers, other solid cancers", "stage": "Phase 1", "therapeutic_area": "Oncology"}
- `` **asset_indication_added** — {"asset": "IMA402 + ICI", "indication": "Melanoma, gynecologic cancers, other solid cancers (combo)", "stage": "Phase 1", "therapeutic_area": "Oncology"}
- `` **asset_indication_added** — {"asset": "IMA401", "indication": "HNSCC, sqNSCLC, other solid cancers", "stage": "Phase 1", "therapeutic_area": "Oncology"}
- `` **asset_indication_added** — {"asset": "Undisclosed bispecific", "indication": "Undisclosed", "stage": "Preclinical", "therapeutic_area": "Oncology"}
- `` **asset_indication_added** — {"asset": "Undisclosed cell therapy", "indication": "Undisclosed", "stage": "Preclinical", "therapeutic_area": "Oncology"}
- `` **asset_added** — {"asset": "anzu-cel"}
- `` **asset_added** — {"asset": "mRNA-4203"}
- `` **asset_added** — {"asset": "IMA203CD8"}
- `` **asset_added** — {"asset": "IMA402"}
- `` **asset_added** — {"asset": "IMA402 + ICI"}
- `` **asset_added** — {"asset": "IMA401"}
- `` **asset_added** — {"asset": "Undisclosed bispecific"}
- `` **asset_added** — {"asset": "Undisclosed cell therapy"}

## Trials (latest)

| NCT | Status | Phase | Last update | Linked assets |
|---|---|---|---|---|
| NCT06946225 | RECRUITING | PHASE1 | 2026-01-08 | anzu-cel; mRNA-4203 |
| NCT03686124 | RECRUITING | PHASE1,PHASE2 | 2025-12-11 |  |
| NCT06743126 | RECRUITING | PHASE3 | 2025-12-04 | anzu-cel |
| NCT05958121 | RECRUITING | PHASE1,PHASE2 | 2025-11-18 |  |
| NCT05359445 | RECRUITING | PHASE1 | 2025-09-09 |  |
